Compare Adobe Systems Inc (ADBE) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? Adobe Systems Inc trades at $256.72 (market cap $104.82B), while Alnylam Pharmaceuticals, Inc. trades at $222.65 (market cap $29.60B). The key difference: Adobe Systems Inc is far larger — about 3.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Adobe Systems Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ADBE | ALNY | |
|---|---|---|
Market Cap | $104.82B | $29.60B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $491.22 |
52-Week Low | $193.41 | $205.48 |
Enterprise Value | $106.26B | $27.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe Inc. (ADBE) is trading at $255.80, down 6.29% in the last 24 hours amid broader tech sector volatility. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $5.96 beating expectations of $5.82. Revenue growth remains robust at $23.77B in 2025, with net income margin expanding to 29.99%. Technical indicators show a bullish moving average signal but neutral oscillators, with key support at $252.
Adobe presents a compelling value opportunity with a P/E of 15.09 below historical averages, though AI competition and CEO transition risks warrant caution. Analyst consensus remains positive with 49.2% buy ratings and $248.86 price target, suggesting potential upside from current levels despite recent selloff.
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
